Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,196.00
(
-1.18%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
104.42
(
-1.27%
)
Bitcoin
81,204.81
(
0.89%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: Protector post# 269784

Tuesday, 08/09/2016 10:21:03 PM

Tuesday, August 09, 2016 10:21:03 PM

Post# of 347009
An example we don't want to happen within Peregrine follows...and good reason why registered letters must be sent to avoid this:

Clearpoint "did not" adjust the authorized shares on their reverse stock split
http://ir.stockpr.com/mriinterventions/company-news/detail/909

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote